Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The effect of cholecalciferol, calcifediol or calcitriol prescription, both aggregated (ADM) and independently, 15 and 30 days prior hospitalization, was studied with respect to the outcome of death at 30 days.

Source: Vitamin D endocrine system metabolites and survival. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients

Study design awaiting verification · Scientific Reports · 2021

Original publication title

Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients

Carlos Loucera; María Peña-Chilet; Marina Esteban-Medina; Dolores Muñoyerro-Muñiz; Román Villegas; Jose Lopez-Miranda; Jesus Rodriguez-Baño; Isaac Túnez; Roger Bouillon; Joaquin Dopazo; Jose Manuel Quesada Gomez

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15 to 30 days before hospitalization were recorded.

The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan: Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50 to 0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61 to 0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57 to 0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.

Authors’ abstract

COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15 to 30 days before hospitalization were recorded.

The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan: Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50 to 0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61 to 0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57 to 0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.

Publication and source details

Original title: Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients

Carlos Loucera; María Peña-Chilet; Marina Esteban-Medina; Dolores Muñoyerro-Muñiz; Román Villegas; Jose Lopez-Miranda; Jesus Rodriguez-Baño; Isaac Túnez; Roger Bouillon; Joaquin Dopazo; Jose Manuel Quesada Gomez

Scientific Reports · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de AndalucíaPAIDI2020-DOC_00350Loucera Carlos Centro de Investigación Biomédica en Red sobre Enfermedades RarasACCI2018/29Peña-Chilet María http://dx.doi.org/10.13039/501100004837Ministerio de Ciencia e InnovaciónPID2020-117979RB-I00Dopazo Joaquin http://dx.doi.org/10.13039/501100004587Instituto de Salud Carlos IIIIMP/0019PI19/00033Dopazo Joaquin Quesada Gomez Jose Manuel http://dx.doi.org/10.13039/100007406Fundación BBVAG999088QDopazo Joaquin http://dx.doi.org/10.13039/100010665H2020 Marie Skłodowska-Curie Actions813533Dopazo Joaquin http://dx.doi.org/10.13039/501100010566Consejería de Salud y Familias, Junta de AndalucíaCOVID-011-2020Dopazo Joaquin http://dx.doi.org/10.13039/100012619Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento SaludableCB16/10/00245Quesada Gomez Jose Manuel

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:26:21.740516+00:00

DOI: 10.1038/s41598-021-02701-5 · PMC8642445